Compare SEDG & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEDG | SRPT |
|---|---|---|
| Founded | 2006 | 1980 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.5B |
| IPO Year | 2015 | 2000 |
| Metric | SEDG | SRPT |
|---|---|---|
| Price | $47.38 | $20.14 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 20 | 28 |
| Target Price | ★ $30.47 | $25.40 |
| AVG Volume (30 Days) | ★ 3.3M | 3.2M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 78.26 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,184,444,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | $19.13 | N/A |
| Revenue Next Year | $13.25 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 31.39 | 15.58 |
| 52 Week Low | $11.00 | $10.42 |
| 52 Week High | $53.28 | $65.69 |
| Indicator | SEDG | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 57.31 | 56.97 |
| Support Level | $30.73 | $16.38 |
| Resistance Level | $48.60 | $23.01 |
| Average True Range (ATR) | 3.60 | 1.19 |
| MACD | 0.70 | 0.54 |
| Stochastic Oscillator | 68.53 | 51.72 |
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.